Male/female adults
Conditions
Interventions
Oral intake of the test food 1 (4 tablets, once daily) for 8 weeks
Oral intake of the test food 2 (4 tablets, once daily) for 8 weeks
Oral intake of the placebo food (4 tablets, once daily) for 8 week
Sponsors
CPCC Company Limited
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women aged 40 to below 70 years at the time of consent acquisition. 2. Subjects with a BMI between 23.0 and less than 30.0. 3. Subjects who can give informed consent to partake in this study, after being provided with an explanation of the protocol detail.
Exclusion criteria
Exclusion criteria: 1. Subjects who cannot discontinue the use of Foods for Specified Health Uses (FOSHU), Foods with Functional Claims, or health supplements (including those containing procyanidin B1 and B3, bonito-derived elastin peptides, black soybean polyphenols, etc) that may affect vascular endothelial function from the time of consent acquisition. 2. Subjects currently undergoing medication treatment (excluding eye drops and nasal sprays). 3. Subjects who are participating in the other clinical trials and/or who have participated in the other clinical trials within 4 weeks prior to the current trial and/or who are planning to participate in the other clinical trials. 4. Subjects with excessive alcohol intake. 5. Subjects who smoke heavily (not less than 21 cigarettes a day) 6. Subjects with previous and/or current medical history of serious diseases in heart, liver, kidney and/or digestive organs. 7. Females who are pregnant or lactating, and females who could become pregnant during the trial period. 8. Subjects with allergies to medications and/or food. 9. Subjects who donated blood or a component (200 mL) within the last 1 month. 10. Male subjects who donated their blood (400 mL) within the last 3 months. 11. Female subjects who donated their blood (400 mL) within the last 4 months. 12. Male subjects whose collected blood volume in total would reach more than 1200 mL within the last 12 months and in this study. 13. Female subjects whose collected blood volume in total would reach more than 800 mL within the last 12 months and in this study. 14. Subjects deemed unsuitable for participation in the trial by the principal investigator or sub-investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-Mediated Dilation (FMD) values | — |
Secondary
| Measure | Time frame |
|---|---|
| Nitric Oxide (NOx) levels Pulse Wave Velocity (PWV) values | — |
Countries
Japan
Contacts
Public ContactMasanori Numa
CPCC Company Limited Clinical Planning Department
Outcome results
None listed